全文获取类型
收费全文 | 21514篇 |
免费 | 2051篇 |
国内免费 | 403篇 |
专业分类
耳鼻咽喉 | 115篇 |
儿科学 | 866篇 |
妇产科学 | 272篇 |
基础医学 | 2213篇 |
口腔科学 | 535篇 |
临床医学 | 1653篇 |
内科学 | 4185篇 |
皮肤病学 | 333篇 |
神经病学 | 1186篇 |
特种医学 | 381篇 |
外国民族医学 | 3篇 |
外科学 | 1485篇 |
综合类 | 2575篇 |
预防医学 | 4662篇 |
眼科学 | 197篇 |
药学 | 1561篇 |
11篇 | |
中国医学 | 530篇 |
肿瘤学 | 1205篇 |
出版年
2023年 | 511篇 |
2022年 | 625篇 |
2021年 | 1284篇 |
2020年 | 1162篇 |
2019年 | 1452篇 |
2018年 | 1312篇 |
2017年 | 950篇 |
2016年 | 655篇 |
2015年 | 748篇 |
2014年 | 1388篇 |
2013年 | 1742篇 |
2012年 | 1049篇 |
2011年 | 1118篇 |
2010年 | 951篇 |
2009年 | 842篇 |
2008年 | 881篇 |
2007年 | 805篇 |
2006年 | 692篇 |
2005年 | 614篇 |
2004年 | 544篇 |
2003年 | 445篇 |
2002年 | 397篇 |
2001年 | 346篇 |
2000年 | 277篇 |
1999年 | 240篇 |
1998年 | 194篇 |
1997年 | 167篇 |
1996年 | 151篇 |
1995年 | 161篇 |
1994年 | 152篇 |
1993年 | 110篇 |
1992年 | 106篇 |
1991年 | 93篇 |
1990年 | 81篇 |
1989年 | 62篇 |
1988年 | 60篇 |
1987年 | 52篇 |
1986年 | 61篇 |
1985年 | 157篇 |
1984年 | 181篇 |
1983年 | 146篇 |
1982年 | 159篇 |
1981年 | 150篇 |
1980年 | 136篇 |
1979年 | 113篇 |
1978年 | 102篇 |
1977年 | 84篇 |
1976年 | 64篇 |
1975年 | 79篇 |
1973年 | 50篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Journal of infection and chemotherapy》2022,28(9):1235-1241
IntroductionThe results from the phase 3 study that evaluated the efficacy and safety of tedizolid phosphate, an oxazolidinone drug, for the treatment of gram-positive ventilated hospital-acquired bacterial pneumonia (vHABP)/ventilator-associated bacterial pneumonia (VABP) compared with linezolid (VITAL study), have been previously reported. We conducted a subgroup analysis to report the data obtained from Japanese patients enrolled in this study.MethodsPatients aged ≥18 years with vHABP/VABP likely to be caused by gram-positive cocci were randomized 1:1 to tedizolid phosphate 200 mg once daily for 7 days or linezolid 600 mg twice daily for 10 days. In both treatment groups, patients with concurrent gram-positive bacteremia were treated for 14 days. Primary efficacy endpoints were day 28 all-cause mortality (ACM) and investigator-assessed clinical response at test-of-cure (TOC) in the intention-to-treat population. Safety outcomes included assessment of treatment-emergent adverse events.ResultsFifty-three Japanese patients were randomized at received study drug (tedizolid, n = 28; linezolid, n = 25). Demographics and characteristics were generally similar between treatment groups. Rates of day 28 ACM were 10.7% and 20.0% with tedizolid and linezolid, respectively (difference, 9.3%; 95% CI, ?10.1 to 28.7). Rates of investigator-assessed clinical cure at TOC were 78.6% and 72.0% with tedizolid and linezolid, respectively (difference, 6.6%; 95% CI, ?16.7 to 29.8). Tedizolid phosphate was generally well tolerated and no new safety concerns were observed in the Japanese subgroup.ConclusionThe results from this subgroup analysis suggest generally favorable efficacy and safety of tedizolid in adult Japanese patients with vHABP/VABP. (ClinicalTrials.gov identifier: NCT02019420). 相似文献
2.
《Nutrition, metabolism, and cardiovascular diseases : NMCD》2022,32(1):151-159
Background & aimsTo determine the trends of self-reported non-adherence rates among adults taking Type 2 medicines (T2D) medicines between 2017 and 2019 and to identify the patterns for the frequently reported reasons for non-adherence in the United States.Methods & resultsData from the National Health and Wellness Survey, a self-administered, internet-based cross-sectional survey of US adults from 2017 to 2019 was used. Non-adherence was measured using the self-reported Medication Adherence Reasons Scale (MAR-Scale). Frequencies were used to identify the reasons for non-adherence for insulin and non-insulin therapies for T2D.Data were obtained from 2983 respondents in 2017, 5416 in 2018, and 5268 in 2019. Based on the MAR-Scale, the self-reported medication non-adherence rate was 25% in 2017, 21% in 2018, and 27% in 2019. The most common reason for non-adherence across all the three years was simple forgetfulness, yet patients reported the lowest mean number of days missing medication for that reason. Though less frequently reported, non-adherence lasted longer when patient did not know how to take their medicines, cost was a reason, or had concerns about the long term effects of the medicines.ConclusionsWith no significant improvement in adherence with T2D medicines over time, regardless of better awareness and extensive diabetes education, focus should be on individualized non-adherence reasons-based interventions. 相似文献
3.
4.
炎症参与了多囊卵巢综合征、子宫内膜异位症、妇科肿瘤等多种疾病的发生、发展,同时也可影响男性生殖功能。饮食在调节慢性炎症中发挥重要作用。膳食炎症指数(dietary inflammation index,DII)是一种新的临床膳食评估工具,将饮食分为促炎饮食和抗炎饮食,用于评估个人膳食整体的炎症潜力。研究显示,促炎饮食与生殖相关疾病的发生风险增加有关,抗炎饮食则与生殖相关疾病的发生风险降低有关。促炎饮食及其组分可升高机体内的炎症水平,促使慢性子宫内膜炎、多囊卵巢综合征、卵巢癌及子宫内膜癌等多种疾病的发生,也可对男性精子浓度和总活力等产生影响,从而导致不孕不育。综述DII与生殖相关疾病的关系和临床机制,并从疾病的预防和控制方面提出饮食建议,以期为临床治疗和护理提供参考。 相似文献
5.
图书馆阅读推广服务品牌化是高校图书馆优质阅读推广服务品质和形象的象征,是图书馆阅读推广服务价值理念的集中体现。山西医科大学图书馆结合读者的阅读需求、能力、行为特征和本馆阅读推广服务的目标,以“让不爱阅读的人爱上阅读-让不会阅读的人学会阅读-让深度阅读的人分享阅读”为品牌定位,设计了“尚书阅读”品牌3级服务体系,即阅读兴趣培养、阅读能力提升和阅读价值彰显。同时还建立了“资源+空间+人才+平台+管理”5级保障机制以维系品牌可持续发展。该研究结果可为国内高校图书馆创建阅读推广服务品牌提供参考借鉴。 相似文献
6.
目的 评价美国国家电器制造协会(National Electrical Manufactures Association, NEMA)最新标准(NU 2-2018)在正电子发射型计算机断层显像/电子计算机断层显像(positron emission tomography/computed tomography, PET/CT)设备性能检测中的作用。 方法 依据最新的NEMA NU 2-2018标准,检测西门子Biograph Vision PET/CT的空间分辨率、灵敏度、散射分数、计数丢失、随机符合、飞行时间分辨率、计数丢失率和随机符合校正精度、图像质量、衰减和散射校正精度及PET与CT配准精度指标。 结果 距视野中心1 cm处横向和轴向空间分辨率分别为3.75 mm和3.76 mm;在视野中心和轴向10 cm处的灵敏度分别为16.83 kcps/MBq和16.67 kcps/MBq;放射性浓度为27.37 kBq/mL时,最大等效噪声计数率为258.26 kcps,散射分数为38.58%;系统时间分辨率为209.82 ps;图像质量模型的对比度恢复系数范围为88.9%~96.2%,背景变异系数范围为2.05%~6.80%,平均肺插件残余误差为2.43%;计数丢失和随机符合校正最大误差为3.9%;距离床板末端 5 cm 和 100 cm处,在距视野中心Y轴1 cm处,PET和CT的配准精度分别为0.46 mm和1.07 mm,在距视野中心X轴20 cm处,PET和CT的配准精度分别为1.06 mm和1.45 mm,在距视野中心Y轴20 cm处PET和CT的配准精度分别为0.85 mm和1.15 mm。 结论 NEMA NU 2-2018标准检测条件更加接近临床,能更好地反映PET/CT设备的系统性能。 相似文献
7.
8.
《American journal of surgery》2023,225(1):113-117
BackgroundRacial disparities in extracorporeal membrane oxygenation (ECMO) outcomes in patients with a broad set of indications are not well documented.MethodsAdults requiring ECMO were identified in the 2016–2019 National Inpatient Sample. Patient and hospital characteristics, including mortality, clinical outcomes, and resource utilization were analyzed using multivariable regressions.ResultsOf 43,190 adult ECMO patients, 67.8% were classified as White, 18.1% Black, and 10.4% Hispanic. Although mortality for Whites declined from 47.5 to 41.0% (P = 0.002), it remained steady for others. Compared to White, Asian/Pacific Islander (PI) race was linked to increased odds of mortalty (AOR = 1.4, 95% CI = 1.1–2.0). Black race was associated with increased odds of acute kidney injury (AOR = 1.4, 95%-CI: 1.2–1.7), while Hispanic race was linked to neurologic complications (AOR 21.6; 95% CI 1.2–2.3). Black and Hispanic race were also associated with increased incremental costs.ConclusionsRace-based disparities in ECMO outcomes persist in the United States. Further work should aim to understand and mitigate the underlying reasons for such findings. 相似文献
9.
目的检索、总结并评价国内外结肠镜检查前肠道准备的最佳证据。方法系统检索国内外专业协会网站、指南网及数据库中关于结肠镜检查前肠道准备的最佳证据。检索时限为从建库至2020年11月30日。由2~4名研究者进行文献质量评价,并对纳入的文献进行证据提取。结果最终纳入12篇文献,包括临床决策1篇,循证指南3篇,证据总结2篇,系统评价6篇。形成了肠镜检查前患者评估、健康教育、肠道准备方法、饮食调整、口服泻药、肠道准备质量评估及失败后补救措施等7个主题的19条证据。结论患者肠镜检查过程中,护理人员、病区医生及内镜医生应密切合作,落实患者评估、健康教育、饮食及药物发放、肠道准备质量评估与反馈等相关措施,帮助患者完成高质量的肠镜检查。 相似文献
10.